NHS funding for Liquid Cartilage hip injection

Liquid Cartilage™ — the UK patient brand for ChondroFiller™, an injectable collagen scaffold — is not available on the NHS and is not funded by any Integrated Care Board in England, including Lincolnshire's. As of mid-2026, NICE has issued no health technology appraisal approving it for routine commissioning; the absence of long-term randomised trial data means the treatment sits outside the standard NHS evidence threshold for funded procedures.

For patients arriving from a GP pathway, the NHS approach to hip cartilage problems follows a well-established sequence: supervised physiotherapy and analgesia first, followed by intra-articular corticosteroid injection for pain flares, and ultimately total hip replacement when conservative measures are exhausted. Hyaluronic acid injections are generally not routinely commissioned by NICE for hip osteoarthritis. There is no NHS-funded regenerative or scaffold-based option for the hip joint at this stage.

Access to Liquid Cartilage™ is therefore entirely private — either self-funded or through private medical insurer pre-authorisation. This is not a clinical rejection of the treatment; it reflects the standard commissioning lag that applies to Class III regenerative devices, which typically takes several years to move from CE marking through NICE evaluation to NHS funding.

Why ChondroFiller is not yet commissioned

The commissioning process for Class III medical devices — the highest-risk regulatory category — follows a predictable sequence: CE marking, real-world clinical adoption, data accumulation, and then formal NICE evaluation. ChondroFiller™ entered clinical use before that evaluation cycle could be completed. The gap is structural, not exceptional.

What NICE points to as the primary barrier is the absence of long-term, hip-specific randomised controlled trial data. No published peer-reviewed RCT has yet been identified for ChondroFiller™ in the hip joint — an honest limitation worth stating plainly. The broader evidence base is more encouraging: over 19,000 cases have been performed globally, and published studies report a mean Harris Hip Score improvement of +33 points, with MOCART MRI regeneration scores of 70–87 across joints. Encouraging early data and a commissioned NHS pathway are, however, different things, and that distinction matters for managing expectations.

ChondroFiller™ is not alone in this position. No comparable UK private regenerative hip injection is currently NHS-commissioned. For patients, the question is one of timing and evidence accumulation — not a signal that the treatment has failed on safety or efficacy grounds.

Private cost of a ChondroFiller hip injection

Pricing for a ChondroFiller™ hip injection is determined by the volume of collagen scaffold required — measured in boxes — rather than by which joint is being treated. Three published guide-cost tiers apply:

• One box (defects up to approximately 3 cm²): guide cost ~£3,000
• Two boxes (up to approximately 4.5 cm²): guide cost ~£5,500
• Three boxes (up to approximately 6 cm²): guide cost ~£8,000
• Complex or multi-compartment presentations: up to approximately £9,800

Each tier is all-inclusive: the initial consultation, real-time ultrasound guidance, the ChondroFiller™ scaffold product itself, IV antibiotic cover, and a six-week follow-up appointment are all bundled into the single fee. Patients can compare this directly with itemised private alternatives without needing to add hidden extras.

One cost that sits outside the procedure fee is a pre-treatment MRI. This scan is required beforehand to measure the defect precisely and confirm which tier applies; the appropriate box count cannot be assumed in advance of imaging. Patients should budget for this separately when planning overall expenditure.

Most single focal hip cartilage defects fall within the one-box tier. Larger surface areas or involvement of more than one compartment of the hip joint may move a case into a higher tier — something the treating clinician confirms once the MRI has been reviewed.

What the hip injection appointment involves

For patients travelling from Lincolnshire or elsewhere outside London, knowing what to expect on the day helps with planning. The appointment is an outpatient session at London Cartilage Clinic on Harley Street — currently the sole UK-certified centre for ChondroFiller™ — and runs to approximately 30–45 minutes. No general anaesthetic is required, no theatre admission, and no overnight stay.

The procedure is carried out under ultrasound guidance throughout. For a hip injection specifically, real-time image guidance is not optional — ChondroFiller™ polymerises into a fixed collagen scaffold within minutes of placement, so accurate positioning before the material sets is essential. The ultrasound allows Professor Paul Lee to confirm needle placement within the hip defect before the scaffold is delivered.

Once in place, the scaffold works through acellular matrix-induced chondrogenesis: it provides a physical structure that recruits the patient's own progenitor cells — drawn from the synovium and subchondral bone — to support the body's own repair processes. The scaffold is gradually resorbed as host tissue matures.

Most patients from Lincolnshire treat the visit as a day trip to London. The journey is a practical consideration rather than a clinical one; the procedure itself carries no theatre recovery time, so patients are typically able to travel home the same day.

Suitable hip candidates for ChondroFiller

Clinical candidacy centres on one central question: is the cartilage damage focal or diffuse? ChondroFiller™ is indicated for isolated, focal Grade III or Grade IV hip cartilage defects — including lesions associated with femoroacetabular impingement (FAI) — where the surrounding cartilage remains reasonably intact. Published evidence reports a mean Harris Hip Score improvement of approximately +33 points in patients treated for focal hip defects; that figure reflects an observed outcome in clinical series, not a guarantee for any individual.

Patients with diffuse, end-stage hip osteoarthritis — where cartilage loss is widespread rather than contained — are generally not suitable candidates for this approach.

Age is not the primary gate. Mechanical joint stability is: a hip that retains structural integrity may be eligible even where a patient has been told the joint is 'bone on bone'. That term covers a range of presentations, and some patients in that category remain suitable candidates once imaging has been reviewed.

Actual candidacy is established by MRI, not by a self-screening checklist. A pre-treatment scan measures the defect precisely and determines the appropriate treatment volume. Patients uncertain whether their hip fits this profile should seek a specialist assessment rather than attempt to self-diagnose from a description alone.

Private insurance cover and booking from Lincolnshire

Booking routes divide into two. Self-funded patients can contact London Cartilage Clinic directly once they have a recent hip MRI confirming defect size and tier. Insured patients must secure written pre-authorisation from their provider before any appointment is made — treatment received without prior approval is unlikely to be reimbursed, regardless of outcome.

Private medical insurance claims for ChondroFiller™ are submitted under CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500. Written approvals are most commonly reported from Bupa, Aviva, and WPA, though coverage is not guaranteed and depends on individual policy terms.

For patients in Lincolnshire and the surrounding region, a hip-specific assessment — including MRI review to confirm candidacy and identify the appropriate treatment volume — can be arranged locally before committing to the journey to London for the injection itself.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without a GP referral for hip assessment, with access points in Sleaford and Grantham.